MicroRNA-30d-5p—A Potential New Therapeutic Target for Prevention of Ischemic Cardiomyopathy after Myocardial Infarction

Author:

Boxhammer Elke1ORCID,Paar Vera1ORCID,Wernly Bernhard2ORCID,Kiss Attila3ORCID,Mirna Moritz1ORCID,Aigner Achim4ORCID,Acar Eylem3,Watzinger Simon3,Podesser Bruno K.3ORCID,Zauner Roland5ORCID,Wally Verena5ORCID,Ablinger Michael5,Hackl Matthias6,Hoppe Uta C.1,Lichtenauer Michael1

Affiliation:

1. Internal Medicine II, Department of Cardiology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria

2. Department of Internal Medicine, General Hospital Oberndorf, Teaching Hospital of the Paracelsus Medical University, 5110 Oberndorf, Austria

3. Ludwig Boltzmann Cluster for Cardiovascular Research, Center for Biomedical Research and Translational Surgery, Medical University Vienna, 1090 Vienna, Austria

4. Rudolf Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, Leipzig University, 04107 Leipzig, Germany

5. Dermatology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria

6. TAmiRNA GmbH, Muthgasse 18, 1110 Vienna, Austria

Abstract

(1) Background and Objective: MicroRNAs (miRs) are biomarkers for assessing the extent of cardiac remodeling after myocardial infarction (MI) and important predictors of clinical outcome in heart failure. Overexpression of miR-30d-5p appears to have a cardioprotective effect. The aim of the present study was to demonstrate whether miR-30d-5p could be used as a potential therapeutic target to improve post-MI adverse remodeling. (2) Methods and Results: MiR profiling was performed by next-generation sequencing to assess different expression patterns in ischemic vs. healthy myocardium in a rat model of MI. MiR-30d-5p was significantly downregulated (p < 0.001) in ischemic myocardium and was selected as a promising target. A mimic of miR-30d-5p was administered in the treatment group, whereas the control group received non-functional, scrambled siRNA. To measure the effect of miR-30d-5p on infarct area size of the left ventricle, the rats were randomized and treated with miR-30d-5p or scrambled siRNA. Histological planimetry was performed 72 h and 6 weeks after induction of MI. Infarct area was significantly reduced at 72 h and at 6 weeks by using miR-30d-5p (72 h: 22.89 ± 7.66% vs. 35.96 ± 9.27%, p = 0.0136; 6 weeks: 6.93 ± 4.58% vs. 12.48 ± 7.09%, p = 0.0172). To gain insight into infarct healing, scratch assays were used to obtain information on cell migration in human umbilical vein endothelial cells (HUVECs). Gap closure was significantly faster in the mimic-treated cells 20 h post-scratching (12.4% more than the scrambled control after 20 h; p = 0.013). To analyze the anti-apoptotic quality of miR-30d-5p, the ratio between phosphorylated p53 and total p53 was evaluated in human cardiomyocytes using ELISA. Under the influence of the miR-30d-5p mimic, cardiomyocytes demonstrated a decreased pp53/total p53 ratio (0.66 ± 0.08 vs. 0.81 ± 0.17), showing a distinct tendency (p = 0.055) to decrease the apoptosis rate compared to the control group. (3) Conclusion: Using a mimic of miR-30d-5p underlines the cardioprotective effect of miR-30d-5p in MI and could reduce the risk for development of ischemic cardiomyopathy.

Funder

Paracelsus Medical University Salzburg

Publisher

MDPI AG

Subject

General Medicine

Reference63 articles.

1. Bhandari, B., Quintanilla Rodriguez, B.S., and Masood, W. (2022). StatPearls, StatPearls Publishing.

2. Mortality From Ischemic Heart Disease;Nowbar;Circ. Cardiovasc. Qual. Outcomes,2019

3. Time is Muscle;Abreu;Arq. Bras. Cardiol.,2019

4. Lifestyle Modification in Secondary Prevention: Beyond Pharmacotherapy;Brinks;Am. J. Lifestyle Med.,2016

5. Lifestyle and hemostatic risk factors for ischemic heart disease: The Caerphilly Study;Yarnell;Arterioscler. Thromb. Vasc. Biol.,2000

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3